Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Shares Outstanding (Weighted Average) (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Shares Outstanding (Weighted Average) data on record, last reported at $72.1 million in Q1 2025.

  • For Q1 2025, Shares Outstanding (Weighted Average) rose 47.08% year-over-year to $72.1 million; the TTM value through Mar 2025 reached $72.1 million, up 47.08%, while the annual FY2024 figure was $61.0 million, 26.99% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $72.1 million in Q1 2025 per CRVS's latest filing, up from $61.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $72.1 million in Q1 2025 and bottomed at $46.6 million in Q1 2022.
  • Average Shares Outstanding (Weighted Average) over 4 years is $50.9 million, with a median of $47.5 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): grew 0.01% in 2023, then soared 47.08% in 2025.
  • A 4-year view of Shares Outstanding (Weighted Average) shows it stood at $46.6 million in 2022, then rose by 3.16% to $48.0 million in 2023, then increased by 26.99% to $61.0 million in 2024, then rose by 18.27% to $72.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Weighted Average) were $72.1 million in Q1 2025, $61.0 million in Q4 2024, and $49.0 million in Q1 2024.